Treatment of allergic rhinitis with desloratadine: Results of a multinational observational study in the middle east gulf region

World Allergy Organization Journal

Volumn 4, Issue 8, 2011, Pages 130-134

  Tamer, M H ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Allergic rhinitis; Desloratadine; Middle East; Nasal congestion; Peak nasal inspiratory flow

Indexed keywords

DESLORATADINE;

ADULT; ALLERGIC RHINITIS; ARTICLE; CONTROLLED STUDY; FEMALE; GULF STREAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; OBSERVATIONAL STUDY; PEAK INSPIRATORY FLOW; PRIORITY JOURNAL;

EID: 80052737796     PISSN: 19394551     EISSN: None     Source Type: Journal    
DOI: 10.1097/WOX.0b013e31822a6e9a     Document Type: Article

References (47)

1. Alsowaidi S, Abdulle A, Shehab A, Zuberbier T, Bernsen R. Allergic rhinitis: prevalence and possible risk factors in a Gulf Arab population. Allergy. 2010;65:208-212.
2. Owayed A, Behbehani N, Al-Momen J. Changing prevalence of asthma and allergic diseases among Kuwaiti children. An ISAAC Study (Phase III). MedPrinc Pract. 2008;17:284-289. (Pubitemid 351799076)
3. Janahi IA, Bener A, Bush A. Prevalence of asthma among Qatari schoolchildren: International Study of Asthma and Allergies in Childhood, Qatar. Pediatr Pulmonol. 2006;41:80-86. (Pubitemid 43117372)
4. Behbehani N, Arifhodzic N, Al-Mousawi M, Marafie S, Ashkanani L, Moussa M, Al-Duwaisan A. The seasonal variation in allergic rhinitis and its correlation with outdoor allergens in Kuwait. Int Arch Allergy Immunol. 2004;133:164-167. (Pubitemid 38314648)
5. Lestringant G-G, Bener A, Frossard P-M, Abdulkhalik S, Bouix G. A clinical study of airborne allergens in the United Arab Emirates. Allerg Immunol (Paris). 1999;31:263-267. (Pubitemid 29526057)
6. Sattar HA, Mobayed H, Al-Mohammed AA, Ibrahim AS, Jufairi AA, et al. The pattern of indoor and outdoor respiratory allergens in asthmatic adult patients in a humid and desert newly developed country. Eur Ann Allergy Clin Immunol. 2003;35:300-305. (Pubitemid 37377054)
7. Ezeamuzie CI, Al-Ali S, Khan M, et al. IgE-mediated sensitization to mould allergens among patients with allergic respiratory diseases in a desert environment. Int Arch Allergy Immunol. 2000;121:300-307. (Pubitemid 30229642)
8. Blaiss MS, Meltzer EO, Derebery MJ, Boyle JM. Patient and healthcare- provider perspectives on the burden of allergic rhinitis. Allergy Asthma Proc. 2007;28(Suppl 1):S4-S10.
9. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Findings from a large online survey. Treat Respir Med. 2005;4:439-446. (Pubitemid 41803329)
10. Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality oflife in allergic rhinitis and asthma. A population-based study of young adults. Am JRespir Crit Care Med. 2000;162:1391-1396.
11. Meltzer EO, Nathan R, Derebery J, Stang PE, Campbell UB, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc. 2009;30:244-254.
12. Sih T, Mion O. Allergic rhinitis in the child and associated comorbidi- ties. Educational Clinical Case Series. Pediatr Allergy Immunol. 2009; 21:e107-e113.
13. Stull D, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Current Med Res Opin. 2007; 23:811-819. (Pubitemid 46631484)
14. Young T, Fin L, Kim H; for the University of Wisconsin Sleep and Respiratory Research Group. Nasal obstruction as a risk factor for sleep-disordered breathing. Allergy Clin Immunol. 1997;99:S757-S762. (Pubitemid 27091592)
15. Walker S, Khan-Wasti S, Fletcher M, Cullinan P, Harris J, Sheikh A. Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: case-control study. J Allergy Clin Immunol. 2007;120:381-387. (Pubitemid 47102376)
16. 2LEN, and AllerGen. Allergy. 2008;63(Suppl 86):8-160. (Pubitemid 351357811)
17. Aerius [summary of prescribing characteristics]. Brussels, Belgium: Schering-Plough Europe Ltd.; 2010.
18. 2LEN study. Int Arch Allergy Immunol. 2010;153:395-402.
19. 2LEN study. Allergy. 2009;64:1516-1523.
20. Holmberg K, Tonnel AB, Dreyfus I, Olsson P, Cougnard J, Mesbah K, Devillier P. Desloratadine relieves nasal congestion and improves quality of life in persistent allergic rhinitis. Allergy. 2009;64:1663-1670.
21. Bachert C, van Cauwenberge P. Desloratadine treatment for intermittent and persistent allergic rhinitis: a review. Clin Ther. 2007;29:1795-1802. (Pubitemid 350212803)
22. Kim K, Sussman G, Hebert J, Lumry W, Lutsky B, Gates D. Deslor- atadine therapy for symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2006;96:460-465.
23. Meltzer EO, Jalowayski AA, Vogt K, Iezzoni D, Harris AG. Effect of desloratadine therapy on symptom scores and measures of nasal patency in seasonal allergic rhinitis: results of a single-center, placebo-controlled trial. Ann Allergy Asthma Immunol. 2006;96:363-368. (Pubitemid 43277178)
24. Simons FER, Prenner BM, Finn A Jr; for the Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003;111:617-622. (Pubitemid 36337887)
25. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001;56:1077-1080. (Pubitemid 33020649)
26. Aberer W. Desloratadine for the relief of nasal and non-nasal allergic symptoms: an observational study. Arch Drug Inf. 2009;doi:10.1111/j(.1753-5174. 2009):00018.x.
27. Mendoza de Morales T, Sanchez F. Clinical efficacy and safety of a combined loratadine-betamethasone oral solution in the treatment of severe pediatric perennial allergic rhinitis. World Allergy Organ J. 2009;2:49-53.
28. Tassinari P, Suarez NR, Centeno J, Velasquez J, Aguirre-Mariscal H, et al; for the LA Desloratadine Study Group. Desloratadine therapy improves allergic rhinitis symptoms in Latin American children aged 6 to 12 years. World Allergy Organ J. 2009;2:42-48.
29. Kaulsay R, Rampal S, Puraviappan P. Effectiveness of desloratadine in improving quality of life in patients with persistent allergic rhinitis. Paper presented at 26th Congress of the European Academy of Allergy and Clinical Immunology (EAACI); June 9-13, 2007; Goteburg, Sweden.
30. Ciebiada M, Gorska-Ciebiada M, Gorski P. The safety and efficacy of desloratadine for the treatment of perennial allergic rhinitis: a multi- center study in Poland. Ann Allergy Asthma Immunol. 2008;100(S1): A91.
31. Dumitrascu D. Improved symptom relief and quality of life with desloratadine in pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2007;119(Suppl):S64.
32. Braverman I, Beiser M, Gilad Z. Desloratadine treatment improves symptoms in patients with seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;119(Suppl):S64.
33. Koosa L. A multicenter, open-label study of desloratadine for the treatment of nasal and ocular symptoms of patients with seasonal allergic rhinitis. JAllergy Clin Immunol. 2008;121:S51.
34. Montagne M. Desloratadine is safe and effective in the treatment of nasal symptoms of persistent allergic rhinitis (PAR): results of two observational studies. JAllergy Clin Immunol. 2006;S320:1236.
35. Carvalho A, Brito U, Cunha J, Torres S, Duarte P, Pereira D. The effect of 4-week treatment with desloratadine 5 milligrams once daily on quality of life and nasal symptoms in subjects with perennial allergic rhinitis and asthma. J Allergy Clin Immunol. 2009;123:S135.
36. Villafuerte CV, Almazan NA, Joson RE. Desloratadine 5 milligrams daily is safe, well tolerated, and effective in subjects in the Philippines with allergic rhinitis or chronic idiopathic urticaria. Allergy. 2009; 64(Suppl 90):S593.
37. Jawad J, Abdelmotaal A, Al-Nawasany O, Gamal A, Tahmeh H, et al. Observational study evaluating nighttime and early morning treatment satisfaction in patients receiving once daily desloratadine for seasonal allergic rhinitis in routine daily practice in Saudi Arabia. Allergy. 2008;63(Suppl 88):S523.
38. Canonica GW, Tarantini F, Compalati E, Penagos M. Efficacy of desloratadine in the treatment of allergic rhinitis: a meta-analysis of randomized, double-blind, controlled trials. Allergy. 2007;62:359-366. (Pubitemid 46398792)
39. Demoly P, Dreyfus I, Dhivert-Donnadieu H, Mesbah K. Desloratadine for the treatment of cypress pollen-induced allergic rhinitis. Ann Allergy Asthma Immunol. 2009;103:260-266.
40. Ciprandi G, Cirillo I, Vizzaccaro A, Civardi E, Barberi S, Allen M, Marseglia GL. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: a pilot study. Int Immunopharmacol. 2005;5:1800-1808. (Pubitemid 41586220)
41. Wilson AM, Haggart K, Sims EJ, Lipworth BJ. Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. Clin Exp Allergy. 2002;32:1504-1509. (Pubitemid 35278920)
42. Berger WE, Lumry WR, Meltzer EO, Pearlman DS. Efficacy of deslo- ratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc. 2006;27: 214-223. (Pubitemid 44153867)
43. Horak F, Stubner P, Zieglmeyer R, Harris AG. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy. 2003;58:481-485. (Pubitemid 36649307)
44. Berger WE, Schenkel EJ, Mansfield LE. Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion. Ann Allergy Asthma Immunol. 2002;89: 485-491. (Pubitemid 36187992)
45. Greiff L, Persson CG, Andersson M. Desloratadine reduces allergen challenge-induced mucinous secretion and plasma exudation in allergic rhinitis. Ann Allergy Asthma Immunol. 2002;89:413-418. (Pubitemid 36188014)
46. Horak F, Stubner UP, Zieglmayer R, Harris AG. Effect of deslorata- dine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol. 2002;109: 956-961. (Pubitemid 34634305)
47. Meltzer EO, Prenner BM, Nayak A; and the Desloratadine Study Group. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1- receptor antagonist, in patients with seasonal allergic rhinitis. Assessment during the spring and fall allergy seasons. Clin Drug Invest. 2001;21:25-32. (Pubitemid 32140474)